Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: developed COVID-19 symptoms. The infection was confirmed via rapid antigen test; developed COVID-19 symptoms. The infection was confirmed via rapid antigen test; This is a literature report for the following literature source(s).  A 25-year-old female patient (unknown if pregnant) received BNT162b2 (COMIRNATY), in Apr2021 as dose 1, single and in Nov2021 as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset Jan2023, outcome "unknown" and all described as "developed COVID-19 symptoms. The infection was confirmed via rapid antigen test". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: infection confirmed. It was unknown if therapeutic measures were taken as a result of covid-19. Additional information: Patient given a 15-day course of Paxlovid as part of a study to see if it would improve her Long COVID symptoms. According to the media article, the patient reported experiencing significant improvement in symptoms. Case report: In May2022, a previously healthy25-year-old woman with a medical history notable only for mild seasonal allergies developed COVID-19 symptoms. The infection was confirmed via rapid antigen test. She had previously received the primary two-shot series of the COVID-19 vaccine(Comirnaty) in April2021 and a Comirnaty booster in November2021. Initially, her Long COVID symptoms were primarily gastrointestinal, including lack of appetite, bloating, weight loss and new food intolerances. Over the next few months, she developed additional symptoms, including fatigue, PEM, exercise intolerance, brainfog, headaches, noise and light sensitivity, and joint pain. In November and December2022, she was treated for small intestinal bacterial overgrowth with two courses of rifaximin, which did not lead to sustained improvement; specifically, after the first course in November, her gastrointestinal symptoms improved for two days before returning top rerifaximin baseline and after these cond course in December, there was no improvement. In January2023, she began a 10-day course of nirmatrelvir/ritonavir outside of  the context of an acute COVID-19infection. At the time, she was taking loratadine and a multivitamin. On day4, she experienced a severe "crash" characterized by increased fatigue, headache, brainfog, sound and light sensitivity, and difficulty remaining upright, walking and balancing. Approximately one month later, she had recovered from the initial crash and her fatigue and PEM had lessened meaningfully; she also experienced limited improvement in brainfog and headaches. In late February and March 2023, she switched from loratadine to fexofenadine and famotidine. In April and May2023, the fatigue, PEM, brainfog, and headache benefits dissipated and her symptoms returned to her pre-nirmaltrevir/ritonavir baseline, and she began taking quercetin, low-dosenaltrexone, and a pro-biotic. As of July2023, she was experiencing some improvements in symptoms,was slowly reintroducing foodsnot tolerated earlier in her disease course, and added gentle swimming multiple times per week with out PEM. She also began a 3-month course of valacyclovir with celecoxib, given the irantiviral and anti-inflammatory properties, respectively, but observed no benefits.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event lack of effect/drug ineffective (CoVID-19) with the suspect product BNT162B2 cannot be fully excluded.,Linked Report(s) : US-PFIZER INC-202500004609 Same patient, different drug and events;